Key Insights

Highlights

Success Rate

86% trial completion

Published Results

18 trials with published results (10%)

Research Maturity

79 completed trials (45% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

7.4%

13 terminated out of 175 trials

Success Rate

85.9%

-0.7% vs benchmark

Late-Stage Pipeline

26%

45 trials in Phase 3/4

Results Transparency

23%

18 of 79 completed with results

Key Signals

18 with results86% success13 terminated

Data Visualizations

Phase Distribution

128Total
Not Applicable (44)
Early P 1 (3)
P 1 (13)
P 2 (23)
P 3 (14)
P 4 (31)

Trial Status

Completed79
Unknown42
Recruiting16
Terminated13
Not Yet Recruiting9
Withdrawn8

Trial Success Rate

85.9%

Benchmark: 86.6%

Based on 79 completed trials

Clinical Trials (175)

Showing 20 of 20 trials
NCT07852416Not ApplicableNot Yet Recruiting

Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy

NCT07612670Not Yet RecruitingPrimary

A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy

NCT04096014Not ApplicableRecruitingPrimary

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

NCT07830303Phase 4Not Yet Recruiting

Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis

NCT06368895Phase 1CompletedPrimary

Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment

NCT05070351Phase 1CompletedPrimary

Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

NCT07799948Not ApplicableRecruitingPrimary

Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPS

NCT06052176Phase 2Active Not Recruiting

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT04862221Phase 2Active Not Recruiting

TReatment for ImmUne Mediated PathopHysiology

NCT05511766Phase 2Completed

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

NCT07046429Not ApplicableRecruitingPrimary

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07727070Active Not Recruiting

Appropriate Management of Hepatic EncePhalopaThy AmonG cirrhOtic patieNts Admitted to Internal Medicine

NCT07683936Early Phase 1RecruitingPrimary

Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery

NCT07587671Not ApplicableNot Yet Recruiting

Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis

NCT05425316CompletedPrimary

Speech in Hepatic Encephalopathy (HE)

NCT07553858Not ApplicableNot Yet RecruitingPrimary

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07528690Phase 2Not Yet RecruitingPrimary

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

NCT07521332Phase 4Recruiting

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

NCT07480096Phase 2Completed

Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems

NCT07454408Phase 1Not Yet RecruitingPrimary

Evaluation of the Outcome of Fecal Microbiota Transplantation

Scroll to load more

Research Network

Activity Timeline